Strategic
Eli Lilly acquires Calytrix Bio
up to $1.5bnPurchase price according to the source
SourcingClub was not involved in this transaction.
The US pharmaceutical group Eli Lilly acquires the unlisted biotech company Calytrix Bio for up to $1.5bn. Calytrix was founded in 2025 and develops antibody therapies for rare blood diseases.
In context
The Deal-Radar lists 20 deals in Healthcare for November 2026, this is the 19th.
Deal-Radar editorial team · responsible: Nick Herbig
Source from the same day: cash.ch , 16 Nov 2026
Who was involved.
- Buyer
- Eli Lilly
- Target
- Calytrix Bio
- Type
- Strategic
- Sector
- Healthcare & Medtech
- Country
USA
- Source dated
- 16/11/2026
- Purchase price
- up to $1.5bn, according to the source
- Source
- cash.ch
Deal-Radar no. 47-018 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits
We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.
November 2026 on the Deal-Radar.
79 of 190 deals so far are of the type Strategic.
- Strategic79
- Add-on32
- Carve-out23
- Funding round23
- Insolvency11
- Buy-out9
- Minority stake6
- Secondary5
- Merger1
- Succession1
New deals every day. By email on Mondays.
All deals of the previous week in one email, with source and adviser.

